​

Nuvectis Pharma Stock (NASDAQ:NVCT)

OwnershipFinancialsChart
Nuvectis Pharma by TradingView

Previous Close

$20.15

52W Range

$5.55 - $29.27

50D Avg

$15.22

200D Avg

$9.67

Market Cap

$512.42M

Avg Vol (3M)

$283.49K

Beta

-0.25

Div Yield

-

NVCT Company Profile

Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

13

IPO Date

Feb 04, 2022

Website

NVCT Performance

NVCT Financial Summary

Dec 25Dec 24Dec 23
Revenue---
Operating Income-$-19.85M$-22.90M
Net Income$-28.87M$-19.00M$-22.26M
EBITDA-$-19.00M$-22.90M
Basic EPS$-1.32$-1.11$-1.43
Diluted EPS$-1.32$-1.11$-1.43

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

TickerCompany
MISTMilestone Pharmaceuticals Inc.
MOLNMolecular Partners AG
TNXPTonix Pharmaceuticals Holding Corp.
CRDFCardiff Oncology, Inc.
RANIRani Therapeutics Holdings, Inc.
IPHAInnate Pharma S.A.
CGENCompugen Ltd.
SAVACassava Sciences, Inc.